Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib

Chagas disease, caused by the protozoan pathogen Trypanosoma cruzi, remains a challenging infection due to the unavailability of safe and efficacious drugs. Inhibitors of the trypanosome sterol 14α-demethylase enzyme (CYP51), including azole antifungal drugs, are promising candidates for development...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Buckner, Frederick S., Bahia, Maria Terezinha, Suryadevara, Praveen Kumar, White, Karen L., Shackleford, David M., Chennamaneni, Naveen Kumar, Hulverson, Matthew A., Laydbak, Joy U., Chatelain, Eric, Scandale, Ivan, Verlinde, Christophe L. M. J., Charman, Susan A., Lepesheva, Galina I., Gelb, Michael H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2012
Gaiak:
Experimental Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3421879/
https://ncbi.nlm.nih.gov/pubmed/22777048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.06244-11
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak